With reports in the literature of its antioxidant and anti-inflammatory action, the HPL OM group showed a reduction in inflammatory markers (TNF-α, MCP-1, and IL-6) (Figure 8), although not significant, suggesting that with longer treatment this result could be different, as was found by Zetina-Equivel et al. (2015) [41] and Somanah et al. (2017) [59]. The gene discussed is TNF; the disease is ocular melanoma.